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In Italy, a law on Medically Assisted Procreation was passed in 2004.
In 2014 the Constitutional Court declared section 4 para. 3 of this Law
to be unconstitutional in the part where it prohibits couples from
accessing heterologous medically assisted procreation techniques if a
condition which causes complete, irreversible sterility or infertility
has been diagnosed. The fast-moving developments in science and
law, and the deep implications that the application of new techniques
− which involve in the context of procreation a third person − can have
in terms of protection of health and not only, makes it appropriate to
keep under review this area, taking into account the pronouncements
of the European Court of Human Rights and regulations in European
countries. In 2004 the Italian Parliament passed a law on medically
assisted procreation (MAP).1 In this regulation the use of heterologous
MAP techniques is forbidden (section 4 para. 3 of Law n. 40/2004).
Some Commentators have defined this ban as a drastic decision,
which clashes with the broader debate which preceded and has also
followed the approval of the law.2 The debate relating to the mainte-
nance in Italian law of the ban on heterologous procreation specifically
introduced by Law No. 40/2004 has had to take into account the pro-
nouncements of the European Court of Human Rights on the case of
S.H. and others against Austria,3,4 concerning the appeal by two cou-
ples of Austrian nationals with infertility problems. The applicants
complained that the prohibition by the Austrian artificial procreation
act of sperm and egg donation for in vitro fertilization – the only med-
ical techniques by which they could successfully conceive children –
violated their right to respect for family life under Article 8 of the
European Convention of Human Rights  and that the difference in
treatment compared to couples who wished to use MAP techniques,
but did not need to use ova or sperm donation for in vitro fertilization,
amounted to a discriminatory treatment, in violation of Article 14 of
the European Convention of Human Rights.
In its judgment of 1 April 2010 the Court held that there had been a
violation of Article 14 in conjunction with article 8 as regards the pro-
hibition of in vitro fertilization with the use of donor ova or sperm,
which was affecting the two couples, but then the case was referred to
the Grand Chamber that underlined that since the use of IVF treatment
gave rise then and continues to give rise today to sensitive moral and
ethical issues against a background of fast-moving medical and scientif-
ic developments, and since the questions raised by the case touch on
areas where there is not yet clear common ground amongst the member
States, …the margin of appreciation to be afforded to the respondent
State must be a wide one, and even if it finds no breach of Article 8 in
the present case, the Court considers that this area, in which the law
appears to be continuously evolving and which is subject to a particu-
larly dynamic development in science and law, needs to be kept under
review by the Contracting States.
In these judgments the Court underlines in fact that MAP is regulated
in detail in some countries, to a certain extent in others and in further
countries not at all. … Donation of sperm is prohibited in Italy,
Lithuania and Turkey, while donation of ova is prohibited in Croatia,
Germany, Italy, Lithuania, Norway, Switzerland and Turkey and that in
the field of medically assisted procreation legal provision are developing
quickly. In Denmark, France and Sweden sperm and ovum donation,
which was previously prohibited, is now allowed since the entry into
force of new legal provisions in 2006, 2004 and 2006 respectively. In
Norway sperm donation for in vitro fertilization has been allowed since
2003, but not ovum donation; since 2007 medically assisted procreation
is also regulated by law in Finland allowing sperm and ova donation.
In Italy the matter was referred to the Constitutional Court that, in
its ruling No. 162/2014, declared section 4 para. 3 of Law No. 40/2004
to be unconstitutional in the part where it prohibits couples from
accessing heterologous MAP techniques if a condition which causes
complete, irreversible sterility or infertility has been diagnosed.
The judgement of the Constitutional Court is firstly based on the
verification whether or not a reasonable balance has been ensured
between protection of reproductive needs and protection of the newly
born child: according the Judges, the absoluteness of the prohibition
under examination is not justified by the requirements to protect the
newly born child, already guaranteed under current legislation.5-8
Section 8 of Law No. 40/2004 establishes that children born follow-
ing the application of medically assisted reproduction techniques have
the status of children born outside of marriage or children recognized
by the couple; Section 231 of the Civil Code takes account of the new
concept of paternity and provides that the husband shall be the father
of any child conceived or born during the marriage; Section 9 of Law
No. 40/2004 specifically establishes that birth as a result of heterolo-
gous assisted procreation will not result in the establishment of legal
relation of parentage between the donor and the newly born child and
that any action seeking to deny paternity will be inadmissible.
The Court first states that the prohibition under examination does
not reflect a practice which has been consolidated over time, since it
was introduced into Italian law in 2004, and nor is it the consequence
of obligations arising from international conventions.
The Court therefore underlines that the decision of the couples
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Significance for public health
Continual scientific progress is making new applications available, with sig-
nificant medical, ethical, legal and social implications, not only for the per-
sons directly concerned. In the area of medically assisted procreation, the
use of heterologous techniques is able to overcome problems of sterility or
infertility for those requesting access to methods of this kind. On the other
hand, legislation is required to regulate the many correlated issues, also
with regard to other parties such as ova or sperm donors and the offspring
resulting from the use of these techniques: the protection of the health of
the offspring; the management of laboratory results obtained during donor
selection tests; the protection of confidentiality; the donor-child traceability;
the number of donations; and individuals’ rights to be fully informed about
their biological origins are just some of the questions confirming that the
implications of new procreation techniques are not restricted merely to the
couples who access them.
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intended to benefit from Law No. 40/ 2004 to become parents and form
a family constitutes an expression of the fundamental, general right to
self-determination, enshrined in articles 2, 3 and 31 of the
Constitution,9 since it concerns the sphere of private and family life,
and that therefore restrictions on this right can only be reasonably,
appropriately justified if the use of the right would jeopardize other
interests of equal importance.
With regard to article 32 of the Constitution,9 the Court finds that the
impossibility of forming a family with children together with the cho-
sen partner, with the aid of heterologous MAP, may have even signifi-
cant adverse effects on the couple’s health.
Moreover, the prohibition is obviously irrational, since the absolute
denial of the right to form a family with children, with its effects on the
right to health, is enforced at the expense of couples suffering from the
most serious reproductive problems, a factor which conflicts with the
ratio legis.
The therapeutic model is indeed the foundation of the regulation of
MAP: the access to the techniques is directed to the protection of
health; sterility and infertility should be addressed as a human health
issue, and reflection on access to MAP should be framed in terms of
access to treatment and health care.10
Then the Court underlines another irrational aspect of the law in
question, in the light of the growth of reproductive tourism, in that it
leads to an unjustified difference in the treatment of the couples suf-
fering the most serious reproductive problems, arising from the finan-
cial resources available to them.
Some underline that couples who travel abroad to undergo MAP face
a considerable psychological stress and risks of unnecessary treatments
imposed on patients (such as PGD in the absence of a significant risk of
genetic disease) to obtain substantial economic gain; prohibition of het-
erologous MAP has also the indirect effect of discriminating couples on
the basis of fortune, the lower the price of treatment the higher the risks
of insufficient guarantees.10
Italian law already regulates some aspects related to the use of het-
erologous MAP. 
Specifically, the Law n. 40/2004  at above mentioned Section 9 pro-
hibits the husband or partner whose tacit consent can be demonstrated
to deny paternity and specifies that an egg or sperm donor does not
acquire any legal parental relationship with the child and cannot estab-
lish any right over or hold any obligations in relation to him or her.
The Legislator, while prohibiting heterologous assisted procreation,
mindful of the fact that these techniques are lawful in many European
countries, had subjected it to appropriate regulations as Italian citizens
were able to travel abroad to take advantage of it.
In more general terms, a number of important markers for the regu-
lation of heterologous MAP can be found in the legislation governing
human tissue and cell donation, that lays down general principles,
applicable notwithstanding the differences between the situations
(concerning for example the accreditation of facilities, the require-
ment that donation must be voluntary and unpaid, the procedures for
consent, the anonymity of the donor and the requirement of protection
from a healthcare point of view).11
Important guidelines are also available in Annex III of Commission
Directive 2006/17/EC, which however has not yet been incorporated
into Italian law: this directive provides minimal regulations for the
selection of reproductive cell donors, in relation to health and medical
history, evaluation of risk factors and the infective disease and genetic
tests to be performed.12
The Conference of the Regions and Autonomous Provinces passed a
document containing operational and clinical guidelines for the appli-
cation of heterologous procreation techniques.13
One fundamental factor deriving from the Italian legal system is that
ova and sperm donation must be a voluntary, altruistic, unpaid act. The
regional guidelines obviously apply the ethical principles of respect for
autonomy, freedom and solidarity and aim to ensure that no possible
economic pressures are brought to bear: the sale of reproductive cells
and any form of remuneration of donors not only reduces the ethical
value of donation and tends to introduce inappropriate commercial fac-
tors into the relationship between the donor and egg or sperm Banks or
between the donor and the recipients, but also encourages speculative
intents in both donors and reproductive cell Banks − which may lead to
fraudulent practices intended to minimize the contraindications to a
donation and/or to maximize the return.14
Prohibiting the remuneration of ovum and sperm donation is an
important measure to combat any potential risk of exploitation of
women particularly from economically disadvantages backgrounds; a
profit would also incite people to withhold information, which may be
relevant for the safety of the donation.
Finding donors altruistically  motivated, reimbursed only for their
effort may be not easy: advertising in order to recruit donors is best per-
formed by an independent, non-profit making body whose duty it is to
promote donation…, based on the principle of solidarity and excluding
financial incentives.15
The Ministry of Health itself considered it necessary to encourage egg
sharing, meaning the unpaid, voluntary donation of surplus ova by
women who undergo MAP treatments, by including an optional declara-
tion of willingness to donate in this way in the informed consent form.
A fundamental phase requiring regulation is egg and sperm donor
selection: the regional guidelines establish selection criteria such as
age (18-40 years for males and 20-35 for females), full possession of
faculties, good health and absence of known genetic abnormalities
within the family, and recommend the tests and analyses to be per-
formed to assist in appropriate medical and genetic assessment,
intended to guarantee the right to health of the parents and child.
During assessment of the donor, consideration must also be given to
potential financial or emotional reasons which may be influencing the
wish to donate and to the donor’s understanding of the significance of
the act of donation.
Another important factor is donor phenotype screening: although
patients are not allowed to choose specific donor phenotypes in order
to prevent eugenic selection, on the other hand, in view of the fact that
for the couple heterologous fertilization is a procedure which enables
them to achieve parenthood by obtaining a pregnancy, the centre must
reasonably ensure that the donor’s main phenotypical characteristics
match those of the recipient couple.
A European Society of Human Reproduction and Embriology
(ESHRE) Task Force on Ethics and Law document explores the ethical
issues involved in the debate about the scope of genetic screening of
gamete donors, mainly consisting of a medical history of the donor and
his/her family and additional tests for some specific disorders.16
Broadening the scope of donor screening, may have the counterproduc-
tive effect of limiting donor availability, either by excluding candidates
with relatively small risks or by scaring potential donors who fear the
consequences that genetic testing may have for themselves; recipients
may also be harmed when wrongly led to believe that given expanding
screening protocols, they can be assured of healthy children: in human
reproduction, genetic risks can never be completely ruled out. In addi-
tion, for the donor and his or her close relatives, genetic screening may
reveal risks knowledge of which may be beneficial  (if the finding allows
for prevention, treatment or other meaningful course of action), but that
may also turn out to be psychologically harmful, especially if findings
reveal a serious genetic risk that is not medically actionable.
Particular importance is given to the consent of the donor, who must
be fully informed about all the aspects related to the donation, the dis-
comfort and risks related to ovarian stimulation and egg retrieval, the
possible implications that testing procedures may have both for him or
herself and for any close relatives, the management of the results of the
tests performed − positive test result should be confirmed before the
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donor is informed, and if they are confirmed the person should be
offered suitable medical advice and clinical work up − and the fact that
he/ she does not acquire any legal parental relationship with the child.
Information and thus consent are also required with regard to the pos-
sible even future implications of the donation: the possibility that the
reproductive cells may be used for research purposes once they are no
longer usable for MAP procedures, and the possibility that the donor may
be contacted, in accordance with strict procedures to protect his/ her con-
fidentiality, in order to request data if the child suffers health problems.
The regulations surrounding the question of donor anonymity and the
protection of confidentiality require a delicate balancing act, in view of
the child’s need to access data about his or her biological origins.
The National Bioethics Committee has underlined that,17 on the one
hand,  the principle of secrecy − that concerns the conception modali-
ties − refers to autonomous choices, while on the other the problem
therefore arises of the legitimacy or not of parental behaviour that
prefers to maintain secrecy, preventing offspring from asking themselves
about their own existence in a complete way, with possible negative
repercussions on family relations, particularly on the primary relation-
ship of trust between children and parents.
Many important reasons are put forward in support of the choice to
remain silent, but in the balancing of the various interests and points of
view… the Committee does not consider that secrecy… is an advisable
option for guarantee the stability of the family and the right to the
respect for their private life of each of its members, nor for safeguarding
the offspring’s peace of mind; furthermore, secrecy is difficult to main-
tain over time and could be harmful to the child also because of genetic
tests that are increasingly widespread and accessible for obtaining infor-
mation about genetic origins with the possibility of identifying the risks
of illness and actual illnesses, and influence reproductive choices on the
basis of the knowledge of the biological parent’s clinical data.
Once secrecy has been lifted, the question therefore arises of the
possibility of obtaining more complete information – connected to
health or also extended to include personal data – with regard to bio-
logical origins. Some of the Committee members support the option of
partial anonymity allowing the offspring to access only those data that,
according to the circumstances, may be necessary for their mental and
physical health; other members recognize the offspring’s right to full
information concerning the reproductive cell donor, indispensable for
the reconstruction of the offspring’s personal identity.
Legal approaches to regulation regarding anonymity and disclosure
vary considerably inside Europe: a number of European countries have
prohibited anonymous donation; in other countries the anonymity is
protected by law;18,19 and regulations gradually change over the years,
in the light of changing social and professional attitudes.
In the UK, in the past disclosure to donor-conceived children about
their origin had been seen as unnecessary and potentially harmful;
now this advice has reversed. In 2005 anonymous gamete donation was
abolished: donor-conceived people born a s a result of donations made
after April 2005 will therefore be able, at the age of 18, to obtaining
identifying information about their donor (while those conceived
before that date will not able to obtain identifying information unless
their donors choose to make themselves identifiable); in 2009 the age
for accessing non-identifying information about the donor was reduced
from 18 to 16.18
Several reasons may move donor-conceived people to obtain infor-
mation about their donor: reasons include finding out what kind of per-
son the donor was and their motivation for donating; identifying fea-
tures or characteristics in common; and accessing medical information.
Such information may help some donor-conceived people integrate their
donor into their existing life story.18
Some commentators consider what are the potential consequences
of heterologous MAP in terms of public health and in particular the
impact of parental anonymity and underline that a significant propor-
tion of the population with no anamnestic familiar data implies serious
difficulty also for ordinary clinical care.20
In most cases information about medical history of the donor would
be of little medical relevance for the donor-conceived person because of
the screening and assessment that potential donors undergo before being
accepted as donors, and because of the low predictive value of much
family history information, the situation may, however, occasionally
arise when factors in the donor’s own medical history or family history
are insufficient to exclude the donor from donating, but may be of future
relevance to the health care of the donor-conceived person.18
Otherwise, the prohibition on donor gamete anonymity in conjunc-
tion with a prohibition on compensation may play a role in the creation
or enhancement of  gamete shortage, and then impede the ability of
infertile people who desire to conceive from achieving conception, with
individual and social ramifications.21
The prohibition on anonymity may also result in fertility tourism: recip-
ients of gamete donors may be forced to go abroad for fertility treatment,
mostly by long wait lists resulting from shortage in their countries.22,23
Some commentators suggest a procedure to balance between the
conflicting rights of donors, parents, and offspring:24 on the one hand
extensive non-identifying information about the donor can be provided
to recipients and their offsprings; on the other hand, a double track pol-
icy could be installed, to give donor the choice to remain anonymous or
to become identifiable, and recipients the choice for an anonymous or
identifiable donor. The Italian Constitutional Court, after citing the
principle of donor anonymity in the regulations concerning the dona-
tion of human tissues and cells,25 refers to the regulation concerning
adoption26 and to a recent ruling27 by the Constitutional Court on the
rule prohibiting access to information regarding the mother who stated
at the child’s birth she did not want to be named: the irreversibility of
the secret is in contrast with Italian Constitution, the provision is
unconstitutional in so far as it does not provide, through a mechanism
established by law, to ensure confidentiality, the possibility for the
judge to question the biological mother at adoptee’s request, for the
purpose of any withdrawal of such a declaration.
In this case, the knowledge of data regarding the biological mother
would enable the adoptee to obtain a family history, essential for pro-
phylaxis interventions or diagnostic tests, since he already devoid of
news about the health history of the paternal branch of the family tree. 
The complexity of the matter seems to suggest the opportunity for
the establishment of ad hoc rules, to guarantee the various and impor-
tant interests involved. Another key point is the number of donations:
according to the Ministry of Health,28 the most reasonable criterion for
regulating this matter, to prevent the birth of too many children to the
same donor, would be to count offspring or families, and link the collec-
tion of reproductive cells from every single donor, their distribution to
the recipient couples and the children born to the donor concerned.
The aforementioned guidelines state that the reproductive cells of
any one donor cannot result in more than ten births, a limit which may
be waived only in those cases in which a couple who have already had
a child by means of MAP wishes to use the procedure again, with the
reproductive cells of the same donor. Another fundamental factor is
donor-child traceability: a complete traceability is essential for counting
the maximum number of children born from the cells of a single donor,
and, of course, for health needs, in compliance with data protection leg-
islation with regard to anonymity. A National Register of donors of
reproductive cells for purposes of MAP of heterologous type is estab-
lished at the National Institute of Health, National Transplant Centre
(Law No. 190/2014). All persons admitted to the donation are recorded
by attributing to each donor of a code; to this end, health facilities must
communicate personal data to the Register, with information systems
likely to ensure the anonymity of the donors themselves. The
dynamism of the matter under consideration therefore, even in light of
the recent ruling by the Constitutional Court and of the deep implica-
                              [Journal of Public Health Research 2015; 4:554]                                              [page 111]
                                                                                                  Perspectives and Debates
[page 112]                                               [Journal of Public Health Research 2015; 4:554]                             
tions that the application of new techniques − which involve in the
context of procreation a third person − can have in terms of protection
of health and not only, makes it appropriate to update current regula-
tions in this field.
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